Prostate cancer vaccine shows promise in clinical trials

Dendreon's cancer vaccine Provenge has shown promise by extending the lives of patients with prostate cancer, according to a study released this week, the first time a cancer vaccine has been shown to improve survival in any malignancy.
Dendreon, a biotech based in Seattle, Wash., said it will wait for three-year data from an additional 98 patients, which it expects in the second half of this year, before seeking
FDA approval for the vaccine. If the data from that study also show a survival benefit, the company said it will begin discussions with the FDA.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.